---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095102"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:39:38.147853+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings reports Q4 net loss $0.19/share; full year loss $1.45/share; merger with Cyclo ongoing

## Summary
- Q4 net loss from continuing ops $4.5M ($0.19/diluted) vs gain $1.3M ($0.06) year ago.
- Full year net loss $34.4M ($1.45/diluted) vs loss $8.4M ($0.36) prior year; includes $89.9M in-process R&D charge.
- Cash and marketable securities $65.9M as of July 31, 2024.
- Merger with Cyclo Therapeutics (CYTH) progressing; Phase 3 study fully enrolled, interim results mid-2025.
- R&D expenses $4.2M for fiscal year, down from $6.3M due to winding down early-stage programs.

## SEC filing metadata
- accession: 0001213900-24-095102
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390024095102/0001213900-24-095102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390024095102/ea0218947-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095102
- JSON: https://secwatch.observer/filing/0001213900-24-095102.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.